CMC in Pharma: What Chemistry, Manufacturing, and Controls Means for Validation Teams

What CMC covers and why it matters for validation

CMC is divided into two main sections in a regulatory submission: the drug substance section (Module 3.2.S in the Common Technical Document format) and the drug product section (Module 3.2.P). Each section covers the full lifecycle from development through commercial manufacturing.

For validation professionals, the CMC section is important because it defines several things you need to validate: the manufacturing process (including critical process parameters and in-process controls), the analytical methods (which need to be validated per ICH Q2), the specifications (which define your acceptance criteria), the container closure system (which needs qualification), and the stability programme (which requires validated stability chambers and LIMS). When CMC changes — and it does, through post-approval changes and supplements — your validation programme needs to respond. A change to a manufacturing process parameter may require re-validation. A change to an analytical method requires method validation. A change to specifications may require updating test case acceptance criteria across your validation documentation.

CMC development and process validation: they are the same conversation

CMC development and process validation Stage 1 (Process Design) are fundamentally the same activity viewed from different perspectives. CMC development builds the scientific understanding of your drug substance and drug product. Process validation Stage 1 builds the scientific understanding of your manufacturing process. The data is often the same — Design of Experiments, critical process parameter identification, design space definition, control strategy development. The difference is the audience: CMC development data goes into your regulatory submission for the health authority, while process validation data goes into your validation documentation for your quality system. The practical implication: your CMC development team and your validation team should be working together from the earliest stages of development, sharing data, aligning terminology, and ensuring that the control strategy defined in CMC is the same control strategy that drives your process validation programme.

Post-approval CMC changes and validation impact

CMC does not end when your product is approved. Post-approval CMC changes — new manufacturing sites, process changes, raw material source changes, specification changes, analytical method changes — are a constant reality of pharmaceutical manufacturing. Each of these changes has validation implications.

The challenge is assessing the validation impact of each CMC change quickly and accurately. A minor change to an analytical method might require method validation only. A significant process change might require full Stage 2 re-validation. A new manufacturing site requires essentially a complete validation programme at the new site (see technology transfer). Your change control system should include a validation impact assessment as a standard step, and your validation team should be involved in evaluating CMC changes from the beginning — not brought in after the change has already been implemented. GxP Copilot integrates with your change control process through Change controls, ensuring that validation impact assessments are linked to the changes that triggered them.

CMC for biologics: where it gets really complicated

If you thought CMC for small molecule drugs was complex, biologics CMC is in a different league. The drug substance is a living cell line rather than a chemical synthesis route. The manufacturing process involves cell culture, purification, and formulation steps that are inherently more variable than chemical manufacturing. The analytical characterisation requires a battery of physicochemical, biological, and immunological tests. And the regulatory framework — including ICH Q5 guidelines for biotech products — adds requirements that do not exist for small molecules. For validation teams working on biologics, this means your validation scope is larger, your analytical method validation programme is more extensive, your process validation requires more batches to demonstrate consistency, and your change control process needs to be more conservative because the impact of manufacturing changes on a biological product is harder to predict. The systems that support biologics CMC — cell line management databases, bioprocess data historians, advanced analytics platforms — all require thorough validation with particular attention to data integrity.

What validation teams should know about CMC

• Read Module 3 of your regulatory submission. If you are validating manufacturing systems and you have not read the CMC section of the submission, you are missing essential context about what the process is supposed to do and why.
• Understand the control strategy. The CMC control strategy defines what needs to be controlled and how tightly. Your validation programme should verify that the systems and processes you are validating actually implement that control strategy.
• Track CMC changes through validation. Every post-approval CMC change should trigger a validation impact assessment. Build this into your change control workflow.
• Align terminology. CMC and validation sometimes use different terms for the same things (critical process parameters vs. key performance indicators, for example). Make sure your teams are speaking the same language.
• Involve validation early in development. The earlier your validation team is involved in CMC development, the smoother the transition from development to commercial manufacturing will be.